ZA202304965B - Combination therapy for treating cancer - Google Patents

Combination therapy for treating cancer

Info

Publication number
ZA202304965B
ZA202304965B ZA2023/04965A ZA202304965A ZA202304965B ZA 202304965 B ZA202304965 B ZA 202304965B ZA 2023/04965 A ZA2023/04965 A ZA 2023/04965A ZA 202304965 A ZA202304965 A ZA 202304965A ZA 202304965 B ZA202304965 B ZA 202304965B
Authority
ZA
South Africa
Prior art keywords
combination therapy
treating cancer
kits
treatment
general
Prior art date
Application number
ZA2023/04965A
Other languages
English (en)
Inventor
Elisabetta Leo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA202304965B publication Critical patent/ZA202304965B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA2023/04965A 2020-10-08 2023-05-04 Combination therapy for treating cancer ZA202304965B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063089195P 2020-10-08 2020-10-08
PCT/EP2021/077703 WO2022074124A1 (en) 2020-10-08 2021-10-07 Combination therapy for treating cancer

Publications (1)

Publication Number Publication Date
ZA202304965B true ZA202304965B (en) 2024-09-25

Family

ID=78293953

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2023/04965A ZA202304965B (en) 2020-10-08 2023-05-04 Combination therapy for treating cancer

Country Status (19)

Country Link
US (1) US20230372333A1 (cg-RX-API-DMAC7.html)
EP (1) EP4225297B1 (cg-RX-API-DMAC7.html)
JP (1) JP7818585B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230083291A (cg-RX-API-DMAC7.html)
CN (1) CN116194110B (cg-RX-API-DMAC7.html)
AU (1) AU2021356123B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023005160A2 (cg-RX-API-DMAC7.html)
CA (1) CA3197056A1 (cg-RX-API-DMAC7.html)
DK (1) DK4225297T3 (cg-RX-API-DMAC7.html)
ES (1) ES3005507T3 (cg-RX-API-DMAC7.html)
FI (1) FI4225297T3 (cg-RX-API-DMAC7.html)
HU (1) HUE069249T2 (cg-RX-API-DMAC7.html)
IL (1) IL301687A (cg-RX-API-DMAC7.html)
MX (1) MX2023004156A (cg-RX-API-DMAC7.html)
PL (1) PL4225297T3 (cg-RX-API-DMAC7.html)
PT (1) PT4225297T (cg-RX-API-DMAC7.html)
TW (1) TW202228693A (cg-RX-API-DMAC7.html)
WO (1) WO2022074124A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202304965B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202304911A (zh) * 2021-04-23 2023-02-01 大陸商南京明德新藥研發有限公司 吡啶醯胺類化合物
WO2023036285A1 (zh) * 2021-09-09 2023-03-16 南京奥利墨斯医药科技有限公司 一种杂芳环类化合物及其应用
US20230250428A1 (en) * 2022-02-07 2023-08-10 Alliance Of Cardiovascular Researchers Method and composition for early detection of malignancies
IL316019A (en) * 2022-04-07 2024-11-01 Astrazeneca Ab Combined treatment for cancer
CA3254948A1 (en) * 2022-04-07 2023-10-12 Astrazeneca Ab Polytherapy for the treatment of cancer
CN121464135A (zh) * 2023-07-07 2026-02-03 优领医药科技(香港)有限公司 含哌嗪并环类衍生物的晶型、其盐型、其制备方法及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6648040B2 (ja) * 2014-05-28 2020-02-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 がん治療のための併用療法としてのエリブリン及びポリ(adpリボース)ポリメラーゼ(parp)阻害剤の使用
TWI837403B (zh) * 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物

Also Published As

Publication number Publication date
HUE069249T2 (hu) 2025-02-28
ES3005507T3 (en) 2025-03-14
DK4225297T3 (da) 2025-01-02
KR20230083291A (ko) 2023-06-09
PT4225297T (pt) 2024-12-30
EP4225297A1 (en) 2023-08-16
JP2023546362A (ja) 2023-11-02
FI4225297T3 (fi) 2024-12-10
US20230372333A1 (en) 2023-11-23
WO2022074124A1 (en) 2022-04-14
AU2021356123B2 (en) 2025-01-09
CA3197056A1 (en) 2022-04-14
EP4225297B1 (en) 2024-10-23
TW202228693A (zh) 2022-08-01
CN116194110B (zh) 2025-06-17
PL4225297T3 (pl) 2025-03-17
CN116194110A (zh) 2023-05-30
MX2023004156A (es) 2023-05-03
IL301687A (en) 2023-05-01
AU2021356123A1 (en) 2023-06-08
BR112023005160A2 (pt) 2023-04-18
JP7818585B2 (ja) 2026-02-20

Similar Documents

Publication Publication Date Title
ZA202300875B (en) Kat6 inhibitor methods and combinations for cancer treatment
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
MX2020009773A (es) Terapia de combinacion.
WO2023097194A3 (en) Bicyclic therapeutic compounds and methods of use in the treatment of cancer
MX2025003477A (es) Uso de reboxetina para el tratamiento de narcolepsia
NO20082567L (no) Kombinasjon av ZD6474 og pemetrexed
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
PH12020500666A1 (en) Pladienolide compounds and their use
PH12022551021A1 (en) Sequential anti-cd19 therapy
MX2020001727A (es) Terapia de combinacion.
MX2019013862A (es) Terapia de combinacion.
WO2024006292A3 (en) Methods of treating cancer
PH12022551371A1 (en) Macrocycles for use in treating disease
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
MX2024014121A (es) Metodos y composiciones para el tratamiento del exceso de glucocorticoides
MX2024012392A (es) Terapia combinada para el tratamiento del cancer
MX2023010512A (es) Agentes de union multiespecificos contra cd40 y cd137 en terapia.
MX2024012368A (es) Terapia combinada para el tratamiento del cancer
PH12022552489A1 (en) V delta1+ t cells for the treatment of myeloid malignancies
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
EP4706653A3 (en) Therapeutic compositions comprising idelalisib and defactinib for treating breast cancers
MX2025006565A (es) Terapia contra el cancer con capivasertib y fulvestrant